Intuitive Surgical vs Cardinal Health
Side-by-side comparison of AI visibility scores, market position, and capabilities
Robotic surgery pioneer with 9,800+ da Vinci systems; da Vinci 5 adds haptic feedback; $8.35B FY2024 revenue; 57,000+ trained surgeons create switching costs; J&J and Medtronic competing.
About
Intuitive Surgical is the global pioneer and dominant leader in robotic-assisted minimally invasive surgery, founded in 1995 and headquartered in Sunnyvale, California. The company trades on Nasdaq (ISRG) and reported $8.35 billion in FY2024 revenue, representing approximately 17% year-over-year growth, with an installed base of nearly 9,800 da Vinci surgical systems deployed in hospitals across 70+ countries. The fourth-generation da Vinci 5 system—launched in 2024—introduced haptic force feedback for the first time, allowing surgeons to sense tissue resistance through robotic instruments, a breakthrough that strengthens Intuitive's technical moat and accelerates system upgrades among existing customers.
Dublin OH pharmaceutical distribution (NYSE: CAH) $230B+ revenue; specialty pharma GLP-1 distribution tailwind, at-Home Solutions growth, medical divestiture to Medline competing with McKesson and Cencora.
About
Cardinal Health, Inc. is a Dublin, Ohio-based healthcare distribution and medical products company — publicly traded on the New York Stock Exchange (NYSE: CAH) as an S&P 500 Health Care component — distributing pharmaceutical products to pharmacies, hospitals, and healthcare providers, and manufacturing and distributing medical and surgical supplies through approximately 44,000 employees. In fiscal year 2025 (ending June 2025), Cardinal Health generated revenues exceeding $230 billion in its Pharmaceutical and Specialty Solutions segment — reflecting the company's role as a pass-through distributor of branded and generic pharmaceuticals at near-zero margin on drug cost, where Cardinal Health earns distribution fees and rebate income on enormous volumes. CEO Jason Hollar has executed a two-segment strategy focused on optimizing pharmaceutical distribution (Pharmaceutical and Specialty Solutions — $227B+ revenue at low margin) and growing medical products profitability (Global Medical Products and Distribution — higher-margin branded surgical products, Cardinal Health brand commodities, and at-Home Solutions). The 2024 divestiture of the medical segment's Cardinal Health Brand product line to Medline Industries for $1.1 billion simplified the medical segment focus toward specialty distribution and home healthcare supply. Cardinal Health's specialty pharmaceutical distribution (oncology, rheumatology, rare disease biologics through Cardinal Health Specialty Solutions) is a growing higher-margin subsegment as pharmaceutical manufacturers contract with specialty distributors for controlled dispensing of limited-distribution drugs.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.